Welcome to our dedicated page for INVO Fertility news (Ticker: IVF), a resource for investors and traders seeking the latest updates and insights on INVO Fertility stock.
INVO Fertility, Inc. operates as a healthcare services fertility company focused on assisted reproductive technology care through the establishment, acquisition and operation of fertility clinics and related technologies. Company news commonly covers clinic expansion, acquired fertility practices, network relationships, laboratory capabilities and the use of the INVOcell medical device for intravaginal culture procedures.
Recurring updates also include intellectual-property developments for INVOcell, operational changes at U.S. fertility clinics, capital-structure actions such as reverse stock splits, shareholder communications, securities-listing compliance matters and financial-reporting status. Recent company materials also identify Family Beginnings and Wisconsin Fertility Institute as part of the clinic platform.
INVO Fertility (Nasdaq: IVF) will participate in H.C. Wainwright's 28th Annual Global Investment Conference, held September 14-16, 2026, at the Lotte New York Palace Hotel in New York City. A pre-recorded virtual company presentation will be available on demand starting September 11, 2026, at 7:00 a.m. ET via the H.C. Wainwright conference portal.
According to INVO Fertility, management will also be available for one-on-one investor meetings during the conference. A slide presentation is accessible on the company’s investor relations website, and investors can schedule meetings through H.C. Wainwright or INVO’s investor relations contacts.
INVO Fertility (Nasdaq: IVF) announced that Dr. Gretchen Collins from its Wisconsin Fertility Institute presented five retrospective platelet-rich plasma (PRP) studies at the 2026 Midwest Reproductive Symposium International in Chicago. The research evaluated ovarian and subendometrial PRP in IVF patients with prior poor response, diminished ovarian reserve, thin endometrium, or other treatment-limiting factors.
Across small cohorts (17–19 patients for ovarian PRP; 9 patients for subendometrial PRP), findings included age- and ovarian-reserve–dependent ovarian response, increased oocyte yield and blastocyst quality, de novo euploid embryos and spontaneous conceptions in some poor responders, higher embryo transfer rates, improved endometrial thickness (mean 6.1 mm to 8.1 mm), restoration of trilaminar pattern, and resolution of intrauterine fluid. All abstracts are retrospective and, according to INVO Fertility, warrant confirmation in larger, prospective studies.
INVO Fertility (Nasdaq: IVF) reported Q2 2026 revenue of $2.18 million, up 17% from $1.86 million in Q2 2025, driven mainly by the February 2026 acquisition of Family Beginnings and growth at Wisconsin and Georgia clinics. Consolidated clinic revenue rose 18% to $2.17 million.
Clinic-Level Adjusted EBITDA (before corporate and public company expenses) was approximately $333,000, up from $164,000 in Q1 2026 and compared to $951,000 for full-year 2025. The company posted net income of $0.9 million versus a $3.6 million net loss a year ago, aided by a $2.5 million gain on remeasurement related to its now wholly owned Birmingham, Alabama clinic and the absence of prior-year discontinued-operation losses from NAYA Therapeutics.
Adjusted EBITDA at the consolidated level was a loss of $1.0 million versus a $0.6 million loss in Q2 2025. Cash rose to $3.7 million at June 30, 2026, from $2.1 million at December 31, 2025. As of August 14, 2026, INVO had 2,506,969 common shares outstanding.
INVO Fertility (Nasdaq: IVF) reported Q1 2026 revenue of $2.02 million, up 23% year-over-year, with consolidated clinic revenue up 22% to $1.98 million. Net loss from continuing operations was $5.5 million, including a $3.8 million non-cash warrant loss.
All Series C-2 Preferred Stock and warrant liabilities were eliminated, stockholders' equity rose 108% to $15.0 million, cash increased to $4.9 million, and total liabilities fell 26% to $9.6 million. The quarter included the Family Beginnings clinic acquisition, bringing the U.S. clinic count to four.
INVO Fertility (Nasdaq: IVF) received a Nasdaq delinquency notice on May 27, 2026 for not timely filing its 2025 Form 10-K and Q1 2026 Form 10-Q with the SEC.
The 10-K was filed on June 2, 2026, and the company is working to complete the 10-Q. Nasdaq has set compliance plan and potential extension deadlines, while IVF shares continue trading.
INVO Fertility (Nasdaq: IVF) reported FY2025 revenue of $6.84 million, up 5% from $6.53 million. Revenue from all clinics reached $8.02 million, up 4%.
Net loss from continuing operations was $(5.3) million versus $(7.7) million, while Adjusted EBITDA was $(3.2) million compared to $(2.2) million.
The company raised about $11.5 million in December 2025 and January 2026 financings, eliminated Series C-2 preferred stock and warrant liabilities, and reported approximately 1.8 million common shares outstanding. INVO acquired Indiana-based Family Beginnings in February 2026 and secured a new patent for a modified INVOcell device, extending protection through 2040.
INVO Fertility (Nasdaq: IVF) received a Nasdaq notice on April 23, 2026 for late filing of its Form 10-K for the year ended December 31, 2025, which was due April 15, 2026.
The notice does not affect the company's current Nasdaq listing or trading. The delay stems from additional time needed to review complex accounting matters, including the tax provision, warrant accounting, and variable interest entity accounting. The company has 60 calendar days to submit a compliance plan; Nasdaq may grant up to 180 days from the due date if the plan is accepted.
INVO Fertility (NASDAQ: IVF) will effect a 1-for-5 reverse stock split of its issued, outstanding and authorized common stock at 12:01 a.m. ET on March 27, 2026.
Post-split trading on The Nasdaq Capital Market will continue under the symbol IVF, the CUSIP will be 44984F880, and issued shares will total approximately 1,615,419. Authorized shares will be adjusted to 50,000,000. Fractional shares for registered holders will be rounded up; beneficial holders in street name will receive cash in lieu per broker procedures.
INVO Fertility (Nasdaq: IVF) announced on March 5, 2026 that it has adopted time-lapse incubation technology at its Wisconsin clinic to enhance laboratory care and patient experience. The company says the FDA-cleared system enables continuous embryo monitoring, supports embryo selection, and provides patients video records of development.
This move aligns with INVO’s stated strategy to invest in modern reproductive technologies and strengthen clinical and laboratory capabilities across its clinic network.
INVO Fertility (Nasdaq: IVF) announced that its Wisconsin Fertility Institute clinic joined the Progyny network effective March 3, 2026. Progyny covers an estimated 7.2 million lives through over 600 employers, giving WFI in-network access to employer-sponsored patients and expanded payor mix.
Eligible patients gain in-network access to diagnostic testing, IVF, fertility preservation and advanced treatments. The company says the move supports scaling clinic reach, deepening payor relationships, and driving long-term growth across its clinic platform.